Skip to main content

How the TGA Regulates Therapeutic Goods in Australia

Scientific Review by Dr. Mitchell Henry Wright

PhD (Microbiology), BBiotech (Hons) · Scientific Advisor

Google Scholar Profile

Last reviewed: 14 March 2026

Dr. Wright serves as Scientific Advisor to Regeniq. He reviews the evidence base underpinning clinical protocols but does not provide clinical services or prescribe medications.

Regulatory Science

You have already used TGA-regulated products today. The paracetamol in your cabinet, the antihistamines on the shelf, the prescription your GP called in last week. Each one passed through a systematic evaluation process before reaching you. Most Australians never consider that regulatory infrastructure until something fails. This page examines what the Therapeutic Goods Administration does, how therapeutic goods earn regulatory approval, and what the Special Access Scheme and Authorised Prescriber pathway involve. It explains why the regulatory framework your telehealth clinic operates under directly affects the quality and safety of your care. Written by a researcher trained in biotechnology and regulatory science.

What the TGA Actually Does

The Therapeutic Goods Administration is Australia's regulatory authority for medicines, medical devices, and biologicals (products derived from living cells or tissues). It operates within the Department of Health and Aged Care under the Therapeutic Goods Act 1989. Its core function is systematic evaluation: assess safety, verify quality, and determine whether a product demonstrates efficacy before therapeutic goods reach patients.

This is not abstract. The paracetamol at your local pharmacy passed through TGA assessment. Your GP's prescription moved through a TGA-regulated supply chain. The vaccine you received last year met TGA standards before a single dose was administered. These regulatory systems operate continuously behind Australian healthcare. Most people never notice them. That changes when a product fails quality standards or a clinic operates outside the framework.

The Australian Register of Therapeutic Goods (ARTG)

The ARTG is the central database of therapeutic goods approved for supply in Australia. If a medicine, medical device, or biological product appears on the ARTG as listed or registered, it has met TGA criteria for quality, safety, and efficacy for its intended use.

You can search the ARTG yourself at tga.gov.au. Enter a product name and verify whether it holds registration. The process takes roughly 30 seconds. Most patients are unaware this tool exists, but it is publicly available and free. When someone claims a product is "TGA-approved," you can verify that claim against the register before your next appointment.

One distinction warrants attention here. Registered products undergo the most rigorous evaluation, including assessment of efficacy data. Listed products, such as some sunscreens and vitamins, meet safety and quality criteria but are not evaluated for efficacy to the same standard. The designation "on the ARTG" does not tell the full story. The category of listing determines the depth of evaluation the product received.

Scheduling: What S4 and S8 Mean for Patients

Medications in Australia fall into schedules that determine how they can be supplied. Two schedules are particularly relevant for telehealth patients: Schedule 4 (prescription only) and Schedule 8 (controlled substances).

Schedule 4 indicates the medication requires a prescription from a registered practitioner. It cannot be purchased over the counter. The prescribing practitioner accepts clinical responsibility for that prescribing decision. This category encompasses a broad range of medications used across many conditions.

Schedule 8 applies stricter controls. These are substances with higher potential for misuse or dependence. Prescribing, dispensing, and record-keeping requirements are correspondingly tighter. State and territory health departments impose an additional layer of oversight for S8 prescribing.

The practical significance is straightforward. The schedule determines who can prescribe a medication, through which regulatory pathway, and with what documentation and oversight. A clinic prescribing S4 medications must follow specific regulatory requirements. If those requirements are not being followed, a direct question applies: what regulatory framework, if any, is governing that prescribing?

TGA Prescribing Pathways for Non-Standard Medications

Not every medication a practitioner might prescribe appears on the ARTG as a standard registered product. In some clinical situations, the specific formulation, dose, or preparation required does not exist commercially. TGA pathways provide patients with regulated access while maintaining safety and quality controls. They are also where confusion, and sometimes exploitation, most frequently occurs.

The Special Access Scheme (SAS)

The SAS enables practitioners to prescribe therapeutic goods not on the ARTG for individual patients, operating through distinct categories.

SAS Category A applies to gravely ill patients where no comparable registered product exists. The practitioner notifies the TGA but does not require prior approval. SAS Category B requires case-by-case TGA approval before prescribing. The practitioner documents why this specific patient requires this specific medication, and the TGA reviews that reasoning. SAS Category C applies to certain lower-risk products where the practitioner submits a notification.

Documentation requirements unify all categories. Each SAS prescription requires recorded clinical reasoning. The TGA retains authority to audit those records at any time. This is not a rubber stamp. It is a traceability system ensuring non-standard prescribing remains justifiable and auditable.

The Authorised Prescriber (AP) Pathway

The TGA grants AP status to practitioners who demonstrate competence to safely prescribe specific therapeutic goods for specific conditions. The practitioner applies, provides evidence of relevant clinical expertise, and obtains endorsement from a specialist college or ethics committee.

Once granted, AP status permits prescribing defined medications to a specified class of patients without individual SAS applications. The practitioner must maintain detailed prescribing records, submit annual reports to the TGA, and accept audit at any time.

AP status communicates something specific: the practitioner voluntarily sought additional regulatory scrutiny, the TGA assessed their competence, and they accepted ongoing oversight obligations. Not every practitioner holds AP status. That distinction is worth understanding.

Why the Pathway Matters to You

If your clinic does not operate through SAS or AP pathways, a practical question follows: where is the medication sourced? What quality controls govern its production? Who documented the prescribing decision, and who can audit it?

These pathways exist so that non-standard medications reach patients through a regulated, traceable chain: practitioner assessment, documented clinical justification, TGA oversight, and dispensing by registered pharmacists. Remove any link and you lose the safety mechanism the system provides.

The same logic applies in research: if you cannot trace your methodology from sample collection through to published result, the finding is unverifiable. In clinical prescribing, traceability from prescribing decision through to dispensed medication makes the process auditable. Auditability is what separates regulated healthcare from unregulated supply.

Compounding and TGA Oversight

Compounding pharmacies prepare medications from raw ingredients based on a practitioner's prescription. They fill a specific clinical niche: when a standard registered product does not meet a patient's clinical requirements, a compounding pharmacy can prepare a custom formulation.

Compounding occupies its own regulatory space. These custom preparations do not undergo individual TGA product review before reaching patients the way registered medicines do. Instead, the TGA regulates the facility itself. A TGA-licensed compounding pharmacy must meet Good Manufacturing Practice (GMP) standards. In practical terms, that means sterile preparation environments, ingredient quality verification, batch records, and potency testing.

The quality of a compounded medication depends directly on the pharmacy producing it. A TGA-licensed facility operating under GMP compliance works within regulatory oversight that is independently verifiable. An unlicensed source does not. Your practitioner's choice of pharmacy is not a minor logistical detail. It is a clinical decision that directly shapes the quality, consistency, and safety of the medication that arrives at your door.

For a detailed examination of how compounding pharmacies operate, what GMP means in practice, and how to verify pharmacy credentials, see our full guide on how compounding pharmacies work under TGA oversight.

Enforcement: What Happens When Clinics Don't Comply

The TGA holds enforcement powers under the Therapeutic Goods Act, and the public record demonstrates that it exercises them.

The most prominent example: in July 2024, the Federal Court imposed a $10.8 million penalty on Evolution Health Pty Ltd for advertising breaches involving SARMs and other therapeutic goods. That clinic had been advertising prescription therapeutic goods directly to consumers. The Therapeutic Goods Act prohibits that practice.

That case was not isolated. In September 2024, the TGA issued $319,000 across 21 infringement notices to four businesses and three individuals advertising prescription weight-loss medicines to consumers. In September 2025, Midnight Health received $198,000 in penalties across 10 infringement notices for advertising prescription-only weight-loss medicines and featuring unapproved testimonials.

A consistent pattern emerges across all three cases. Clinics marketed prescription medications as consumer products. They crossed the regulatory boundary between clinical practice and direct-to-consumer advertising. The financial penalties are documented. The enforcement actions are public record.

A clinic that operates within TGA pathways uses precise language on its website and does not name specific compounds in marketing material. It does so because the Therapeutic Goods Act requires it. That compliance is a patient safety mechanism. Prescribing decisions belong in clinical consultations between a practitioner and a patient, not on landing pages.

Frequently Asked Questions

Search the Australian Register of Therapeutic Goods (ARTG) at tga.gov.au. You can look up a product by name, active ingredient, or sponsor. If the product appears as 'registered' or 'listed,' it has met the corresponding TGA evaluation criteria. Note that 'registered' and 'listed' represent different evaluation levels. If a product does not appear on the ARTG, your practitioner may prescribe it through the Special Access Scheme or Authorised Prescriber pathway, each with its own regulatory requirements.

The Special Access Scheme (SAS) provides access to non-ARTG products on a case-by-case basis, with each prescription requiring documented clinical justification. The Authorised Prescriber (AP) pathway permits practitioners with specific TGA approval to prescribe certain medications to a defined patient group without individual SAS applications. AP status requires demonstrated clinical competence and records subject to TGA audit. The key distinction: SAS is per-patient approval; AP is practitioner-level approval for a defined scope.

No. TGA evaluation assesses quality, safety, and efficacy at a population level, but individual clinical factors remain critical. Your medical history, current medications, and known allergies all influence whether a medication is appropriate for you. Population-level evidence establishes that a therapy can work; individual clinical assessment determines whether it suits a specific patient. A practitioner reviews those factors before prescribing. The TGA sets the regulatory framework, and your practitioner applies it to your circumstances.

Ask which TGA pathway your prescription follows: whether it is an ARTG-registered product, prescribed under the Special Access Scheme, or through Authorised Prescriber status. Ask whether the dispensing pharmacy is TGA-licensed and whether the prescribing practitioner is AHPRA-registered. These are verifiable facts, not matters of opinion. A clinic operating within these regulatory frameworks will answer those questions directly and without hesitation.

References

  1. [1] Hotaki LT, et al. "Comparative Expedited Regulatory Programs of U.S Food & Drug Administration and Project Orbis Partners." Therapeutic Innovation & Regulatory Science, vol. 57, 2023, pp. 871-882. [Link]
  2. [2] MacPhail SL, et al. "Medicinal Cannabis Prescribing in Australia: An Analysis of Trends Over the First Five Years." Frontiers in Pharmacology, vol. 13, 2022, 885655. [Link]
  3. [3] Moulds RF. "Promoting and advertising therapeutic goods. Trade Practices Commission report on self-regulation." Medical Journal of Australia, vol. 157, no. 8, 1992, pp. 513-514. [Link]
  4. [4] Rudge C, et al. "Regulating autologous stem cell interventions in Australia: updated review of the direct-to-consumer advertising restrictions." Australian Health Review, vol. 45, no. 5, 2021, pp. 594-600. [Link]
  5. [5] Huth K, et al. "Patient Safety in Ambulatory Pediatrics." Current Treatment Options in Pediatrics, vol. 6, 2020, pp. 89-101. [Link]

TGA-Compliant Telehealth Prescribing Across Australia

Regeniq is a registered Australian telehealth clinic. Every prescription follows documented TGA-compliant pathways, including the Special Access Scheme and Authorised Prescriber framework where clinically indicated. AHPRA-registered practitioners conduct all consultations through practitioner-led live video calls that meet the same regulatory and clinical standard as in-person visits. Our evidence-based approach requires blood work and pathology review (laboratory tests assessing your health markers) before any prescribing decision. This reflects the same principle that governs good research methodology: you gather the data before forming a conclusion. When a prescription is clinically appropriate, a licensed compounding pharmacy dispenses it. Registered pharmacists staff that pharmacy under TGA and Good Manufacturing Practice (GMP) standards. Dr. Mitchell Henry Wright, our scientific advisor, holds a PhD in Microbiology and a Bachelor of Biotechnology (Honours). He reviews the evidence base behind our clinical protocols. Every medical consultation at Regeniq follows documented TGA prescribing pathways. We follow AHPRA advertising guidelines and TGA therapeutic goods rules because regulatory compliance is a patient safety mechanism, not an administrative formality.

Related Articles

Are Peptides Legal in Australia?

· 9 min read

Peptides and Steroids: What's the Difference?

· 7 min read

The Performance Gap: Why Your Recovery Protocol Is Failing Your Progress

· 7 min read

Want to learn more about evidence-based telehealth?

Our Clinical Approach